USA Core PPI (YoY) for Sep 7.200% vs 7.300% prior reading.
BTIG Maintains Buy on Liquidia, Raises Price Target to $17
BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $14 to $17.
Related Posts
Medical Marijuana For Chronic Pain: University Of Michigan Conducting More Studies
Researchers at the University of Michigan, MoreBetter (Releaf App), LEVEL and Overcome announced they are recruiting California residents to participate in a 12-week study focusing on the efficacy of different cannabinoid capsules and tablets for managing chronic pain "related to Fibromyalgia, Rheumatoid Arthriti
‘Rio Tinto Faces Possible Norway Fund Divestment Over Alleged Deforestation Links’ – WSJ
https://www.wsj.com/articles/rio-tinto-faces-possible-norway-fund-divestment-over-alleged-deforestation-links-de34bec2?mod=latest_headlines The ethics adviser to the Norwegian sovereign-wealth fund has told the
SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $60
SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $65 to $60.